Changes of Ubiquitin C-terminal Hydrolase-L1 Levels in Serum and Urine of Patients with White Matter Lesions.

Yuyuan Li,Yang Sun,Jian Li,Zhe Wang,Yongzhong Lin,Ling Tang,Dandan Xia,Tiezheng Zheng,Xiaohan Yang,Li Sha,C. K. Sun
DOI: https://doi.org/10.1016/j.jns.2015.07.033
IF: 4.4
2015-01-01
Journal of the Neurological Sciences
Abstract:OBJECTIVES:Ubiquitin carboxy-terminal hydrolase-L1 (UCH-L1) has been established as a potential biomarker of neuronal damage. There is not much information about the effects of white matter lesions (WMLs) on serum and urine UCH-L1 levels in white matter disease patients. This study was aimed to assess whether serum or urine UCH-L1 levels are a reliable marker of brain damage in patients with WMLs. DESIGN AND METHODS:Serum and urine levels of UCH-L1 were assessed in 125 patients with dizziness, hypertension, type 2 diabetes mellitus, or dyslipidemia. Of these 125 patient cases, 41 showed periventricular WMLs (P-WMLs), 46 showed subcortical WMLs (S-WMLs), and 38 displayed no well-defined WMLs (controls). RESULTS:Serum UCH-L1 levels were significantly different between the WML group and controls (p<0.05). Further subgroup analysis proved that serum UCH-L1 levels in participants with S-WMLs were significantly increased when compared with controls (p<0.001), but there was no significant differences between controls and patients with P-WMLs (p>0.05). However, urine levels of UCH-L1 were similar between these three groups (p>0.05). In addition, multivariate analysis showed that increased serum UCH-L1 levels were independently associated with the severity of WMLs using Fazekas scale (β=0.432, p<0.001). CONCLUSIONS:These findings suggest that serum UCH-L1 levels may serve as a novel biomarker for neuronal damage from WMLs, especially S-WMLs.
What problem does this paper attempt to address?